138 related articles for article (PubMed ID: 17163402)
1. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin.
Ribatti D; Nico B; Mangieri D; Longo V; Sansonno D; Vacca A; Dammacco F
Histol Histopathol; 2007 Mar; 22(3):285-9. PubMed ID: 17163402
[TBL] [Abstract][Full Text] [Related]
2. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin.
Marimpietri D; Nico B; Vacca A; Mangieri D; Catarsi P; Ponzoni M; Ribatti D
Oncogene; 2005 Oct; 24(45):6785-95. PubMed ID: 16007159
[TBL] [Abstract][Full Text] [Related]
3. Total alkaloids of Rubus alceifolius Poir shows anti-angiogenic activity in vivo and in vitro.
Zhao J; Lin W; Zhuang Q; Zhong X; Cao Z; Hong Z; Peng J
Integr Cancer Ther; 2014 Nov; 13(6):520-8. PubMed ID: 25148840
[TBL] [Abstract][Full Text] [Related]
4. Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?
Shen FZ; Wang J; Liang J; Mu K; Hou JY; Wang YT
Int J Exp Pathol; 2010 Feb; 91(1):10-6. PubMed ID: 20096070
[TBL] [Abstract][Full Text] [Related]
5. Natural antioxidant pedicularioside G inhibits angiogenesis and tumourigenesis in vitro and in vivo.
Mu P; Gao X; Jia ZJ; Zheng RL
Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):30-4. PubMed ID: 17973903
[TBL] [Abstract][Full Text] [Related]
6. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
7. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.
Tanaka S; Arii S
Int J Clin Oncol; 2006 Apr; 11(2):82-9. PubMed ID: 16622743
[TBL] [Abstract][Full Text] [Related]
8. Ta1722, an anti-angiogenesis inhibitor targeted on VEGFR-2 against human hepatoma.
Zheng L; He X; Ma W; Dai B; Zhan Y; Zhang Y
Biomed Pharmacother; 2012 Oct; 66(7):499-505. PubMed ID: 22854322
[TBL] [Abstract][Full Text] [Related]
9. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
10. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.
Marimpietri D; Brignole C; Nico B; Pastorino F; Pezzolo A; Piccardi F; Cilli M; Di Paolo D; Pagnan G; Longo L; Perri P; Ribatti D; Ponzoni M
Clin Cancer Res; 2007 Jul; 13(13):3977-88. PubMed ID: 17606732
[TBL] [Abstract][Full Text] [Related]
11. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.
Dai LC; Wang X; Yao X; Lu YL; Ping JL; He JF
World J Gastroenterol; 2007 Feb; 13(8):1208-13. PubMed ID: 17451201
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives.
Sun HC; Tang ZY
J Cancer Res Clin Oncol; 2004 Jun; 130(6):307-19. PubMed ID: 15034787
[TBL] [Abstract][Full Text] [Related]
14. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line.
Campostrini N; Marimpietri D; Totolo A; Mancone C; Fimia GM; Ponzoni M; Righetti PG
Proteomics; 2006 Aug; 6(15):4420-31. PubMed ID: 16888724
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
17. A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.
Özcetin A; Aigner A; Bakowsky U
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):711-5. PubMed ID: 23891770
[TBL] [Abstract][Full Text] [Related]
18. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
19. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.
Semela D; Piguet AC; Kolev M; Schmitter K; Hlushchuk R; Djonov V; Stoupis C; Dufour JF
J Hepatol; 2007 May; 46(5):840-8. PubMed ID: 17321636
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
